Citi Has Buy on Amgen

Citi Investment Research is out with a research report on Amgen

and it has a Buy rating and a $65 price target on shares. In a note to clients, Citi Investment Research writes, "─Our analysis of weekly IMS scrips suggests that US Prolia sales are tracking at $47.6M vs. Citi Q4 ests of $38M. IMS scrip data indicates that Prolia TRx is tracking up 43.3% q/q. This is based on five of the total 13 weeks for Q4." Shares of AMGN are off 60 cents to $57.26, a loss of 1.05%.